Kursprognose für City Therapeutics, Inc. Common Stock (CTY)CTYCity Therapeutics, Inc. Common Stock

City Therapeutics, Inc. is currently not a strong buy due to its recent performance and valuation metrics. The stock has dropped 7.28% over the last five days and has a very low forward P/E ratio of 0, indicating uncertainty in future earnings. While the year-to-date change is positive at 15.39%, the current price of 20.77 does not reflect strong growth potential given the high price-to-sales ratio of 72.89. The main risk is the lack of significant insider or hedge fund activity, which suggests a lack of confidence from major investors.

City Therapeutics, Inc. Common Stock (CTY) last closed at $20.7099991, losing -6.46%. These facts feed the 1-day and 1-week CTY price prediction above.